Intact Investment Management Inc. Purchases 14,300 Shares of Pfizer Inc. (NYSE:PFE)

Intact Investment Management Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 3.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 437,500 shares of the biopharmaceutical company’s stock after buying an additional 14,300 shares during the period. Intact Investment Management Inc.’s holdings in Pfizer were worth $12,661,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of PFE. China Universal Asset Management Co. Ltd. acquired a new position in Pfizer during the 1st quarter valued at $315,000. Norden Group LLC raised its stake in Pfizer by 26.8% during the 1st quarter. Norden Group LLC now owns 30,336 shares of the biopharmaceutical company’s stock valued at $842,000 after purchasing an additional 6,404 shares during the last quarter. Central Pacific Bank Trust Division acquired a new position in Pfizer during the 1st quarter valued at $136,000. GSA Capital Partners LLP acquired a new position in shares of Pfizer in the 1st quarter valued at $439,000. Finally, AA Financial Advisors LLC acquired a new position in shares of Pfizer in the 1st quarter valued at $318,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PFE. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Barclays increased their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Citigroup began coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Stock Down 0.7 %

Shares of NYSE:PFE opened at $28.09 on Monday. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company’s 50-day moving average price is $29.03 and its two-hundred day moving average price is $28.62. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a market cap of $159.18 billion, a P/E ratio of 37.96, a P/E/G ratio of 0.90 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the firm earned ($0.17) EPS. The company’s revenue was up 31.2% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.98%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.